Provided is a cross-linked polysaccharide gel composition used in cosmetics and medicine fields, and more particularly, to a hyaluronic acid gel composition having durability capable of maintaining durability for a long time within a living body without increasing a cross-linked bond rate by including a material having functions of decomposition inhibition and antioxidation of polysaccharide in cross-linked polysaccharide gel. In addition, the composition is a hydro gel complex in which ursolic acid is contained in non-cross-linked or cross-linked polysaccharides.

Crystalline cellulose gels useful in the stabilization of emulsions, including nanoemulsions, and for acting as cryptands or clathrates, and methods for their use and production are provided. In some embodiments, the emulsion is an oil-in-water emulsion. In some embodiments, such emulsions and/or vesicles produced in such emulsions, and/or the crystalline cellulose gel itself 15 are useful in the fields of drug delivery, pharmaceuticals, cosmetics, feed and food, paints and coatings, mining, or oil and gas recovery.

Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.

Described herein are compounds, compositions and methods for modification of the surface of a living cell with a therapeutically relevant targeting moiety. Also described herein are methods for treating disease states, such as acute myocardial ischemia or infarction, with said compositions, in a subject.

Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.

Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled via a boronic ester to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. EGFR-targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.

The invention provides immunoconjugates and methods of using the same.

Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated glucocerebrosidase conjugated to the small molecules, which compositions may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease.

Provided herein, inter alia, are compositions, methods of detecting a diseased tissue in a subject, and methods of treating a subject having cancer.

A process is provided, comprising reacting a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne, wherein the (hetero)aryl 1,3-dipole compound comprises a 1,3-dipole functional group bonded to a (hetero)aryl group, and wherein the (hetero)aryl 1,3-dipole compound is a (hetero)aryl azide or a (hetero)aryl diazo compound; wherein:

(i) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound comprises a substituent

(ii) the (hetero)aryl group of the (hetero)aryl 1,3-dipole compound is an electron-poor (hetero)aryl group

and wherein the (hetero)cycloalkyne is a (hetero)cyclooctyne or a (hetero)cyclononyne according to Formula (1). The invention also relates to the products obtainable by the process according to the invention.